The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Chronic heart failure and hypoalbuminaemia are linked to a poor antibody response at 3 months after the third dose of the ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The mRNA metabolism passively shapes the levels of an mRNA modification called m6A within a steady-state cell and upon stress.

Summary: New research reveals how a tiny chemical mark on RNA helps wire the brain during development. Scientists discovered ...

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...

Many leading pharma and biotechs have invested in messenger RNA (mRNA) technology to develop COVID-19 vaccines and are now exploring their potential in other disease areas (Figure 1).

RNA is generally single-stranded, as DNA is transcribed by RNA polymerases into mRNA (messenger RNA), which is read by ribosomes to generate protein (translation).

The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.